Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1636058
PUBLISHER: IMARC | PRODUCT CODE: 1636058
Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2025-2033
PUBLISHED:
PAGES: 143 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global Duchenne muscular dystrophy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.46% during 2025-2033. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.
Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.
Duchenne Muscular Dystrophy Drugs Market Trends:
The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.
Key Market Segmentation:
Product Type Insights:
- Corticosteroids
- Prednisolone
- Prednisone
- Deflazacort
- Pain Management Drugs
Therapeutic Approach Insights:
- Mutation Suppression
- Exon Skipping
- Steroid Therapy
End User Insights:
- Hospitals
- Clinics
- Home Care Settings
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
- The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.
Competitive Landscape:
- The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
- 1. How big is the global Duchenne muscular dystrophy drugs market?
- 2. What is the expected growth rate of the global Duchenne muscular dystrophy drugs market during 2025-2033?
- 3. What are the key factors driving the global Duchenne muscular dystrophy drugs market?
- 4. What has been the impact of COVID-19 on the global Duchenne muscular dystrophy drugs market?
- 5. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the product type?
- 6. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the therapeutic approach?
- 7. What is the breakup of the global Duchenne muscular dystrophy drugs market based on the end user?
- 8. What are the key regions in the global Duchenne muscular dystrophy drugs market?
- 9. Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?
Product Code: SR112025A6715
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Duchenne Muscular Dystrophy Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Corticosteroids
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Prednisolone
- 6.1.2.2 Prednisone
- 6.1.2.3 Deflazacort
- 6.1.3 Market Forecast
- 6.2 Pain Management Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Therapeutic Approach
- 7.1 Mutation Suppression
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Exon Skipping
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Steroid Therapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Home Care Settings
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 FibroGen Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Italfarmaco S.p.A.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 PTC Therapeutics Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 Santhera Pharmaceuticals
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Sarepta Therapeutics Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.1 FibroGen Inc.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
Product Code: SR112025A6715
List of Figures
- Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion USD), 2019-2024
- Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
- Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2024
- Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2024
- Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2024
- Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2024
- Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million USD), 2019 & 2024
- Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2024
- Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
- Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
- Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2024 and 2033
- Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
- Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million USD), 2025-2033
- Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
- Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
- Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
- Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.